Letter

Adjuvant trastuzumab for breast cancer: Editorial does not mention health economics of drug

BMJ 2005; 331 doi: 10.1136/bmj.331.7526.1203 (Published 17 November 2005)
Cite this as: BMJ 2005;331:1203.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. E Hamish McLaren (handsmclaren@btinternet.com), retired consultant physician
  1. Badmany House, Beith, Ayrshire KA15 2JL

    EDITOR—Why does the BMJ, which promotes itself as a journal dedicated to evidence based medicine, publish an editorial that talks only of the hazard ratio of a treatment without any reference to the absolute reduction in recurrence observed? …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular